# Alpa Laboratories (NSE: ALPA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ALPA · Pivot · prices to 22 Oct 2026

Alpa Laboratories (NSE: ALPA) closed at ₹51.70 on 22 Oct 2026, up 0.90% on the day. With a market capitalisation of ₹109 Cr, it ranks 2614th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 7.3× trailing earnings, against a return on equity of 7.6% in FY26. Over the past year the share price has fallen 41.8%. Its 52-week range is ₹46.10 (30 Mar 2026) to ₹93.85 (31 Oct 2025); the last close is 44.9% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹31 Cr (−21.3% year on year) and net profit ₹1 Cr, on a consolidated basis. Promoters held 57.19% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹51.70 |
| Market cap | ₹109 Cr |
| P/E (trailing) | 7.3 |
| ROE | 7.6% (FY26) |
| ROCE | 8.9% (FY26) |
| Debt to equity | 0.01 |
| 52-week high | ₹93.85 (31 Oct 2025) |
| 52-week low | ₹46.10 (30 Mar 2026) |
| 1-year return | −41.8% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹31 Cr | −21.3% | ₹1 Cr | — | ₹0.24 |
| Q3 FY26 | ₹29 Cr | +11.1% | ₹2 Cr | −78.7% | ₹0.90 |
| Q2 FY26 | ₹26 Cr | +5.3% | ₹0 Cr | −98.6% | ₹0.05 |
| Q1 FY26 | ₹19 Cr | −10.9% | ₹12 Cr | +130.8% | ₹5.59 |
| Q4 FY25 | ₹40 Cr | +69.1% | −₹2 Cr | −159.7% | −₹0.95 |
| Q3 FY25 | ₹26 Cr | −4.2% | ₹9 Cr | +97.3% | ₹4.23 |
| Q2 FY25 | ₹25 Cr | −23.0% | ₹8 Cr | +32.8% | ₹3.66 |
| Q1 FY25 | ₹21 Cr | −15.7% | ₹5 Cr | +68.3% | ₹2.42 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹112 Cr | ₹20 Cr |
| FY24 | ₹109 Cr | ₹17 Cr |
| FY23 | ₹93 Cr | ₹13 Cr |
| FY22 | ₹112 Cr | ₹14 Cr |
| FY21 | ₹98 Cr | ₹7 Cr |
| FY20 | ₹86 Cr | ₹2 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 57.19%
- Foreign institutions: 0.35%
- Domestic institutions: 0.07%
- Non-institutions: 42.39%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Godavari Drugs](https://app.pivotnow.in/stock/GODAVARI) | — | ₹120 Cr | — | — |
| [Parnax Lab](https://app.pivotnow.in/stock/PARNAXLAB) | ₹104.00 | ₹119 Cr | 10.1 | — |
| [Makers Labs](https://app.pivotnow.in/stock/MAKERSL) | ₹191.02 | ₹113 Cr | 48 | — |
| [Pharmaids Pharm](https://app.pivotnow.in/stock/PHARMAID) | — | ₹113 Cr | — | — |
| [BALAXI PHARMACEUTICALS](https://app.pivotnow.in/stock/BALAXI) | ₹20.31 | ₹112 Cr | 78.1 | — |
| [Mercury Labs](https://app.pivotnow.in/stock/MERCURYLAB) | — | ₹102 Cr | — | — |

## Questions and answers

### What is the share price of Alpa Laboratories today?

Alpa Laboratories (NSE: ALPA) last closed at ₹51.70 on 22 Oct 2026. Its 52-week high is ₹93.85 and its 52-week low is ₹46.10.

### What is the market cap of Alpa Laboratories?

Alpa Laboratories' market capitalisation is ₹109 Cr (₹109 Cr) at the 22 Oct 2026 close, ranking 2614th among the NSE companies Pivot tracks.

### What is the P/E ratio of Alpa Laboratories?

Alpa Laboratories trades at a trailing P/E of 7.3. The median P/E of the 3 closest Pharma & Healthcare peers by market cap is 48.

### What is the ROE and ROCE of Alpa Laboratories?

Return on equity was 7.6% in FY26 and return on capital employed was 8.9% in FY26 (consolidated figures).

### Is Alpa Laboratories a debt-free company?

Alpa Laboratories is close to debt-free: its debt-to-equity ratio was 0.01 in FY26.

### What were Alpa Laboratories' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Alpa Laboratories reported revenue of ₹31 Cr, −21.3% year on year, and net profit of ₹1 Cr.

### How has Alpa Laboratories stock performed over the last year?

Alpa Laboratories' share price has fallen 41.8% over the past year, −22.0% over three months and −14.3% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Alpa Laboratories?

As of 30 Jun 2026: promoters 57.19%, foreign institutions 0.35%, domestic institutions 0.07%, non-institutions 42.39%.

### Who are Alpa Laboratories' competitors?

The listed Pharma & Healthcare companies closest to Alpa Laboratories by market cap are Godavari Drugs, Parnax Lab, Makers Labs, Pharmaids Pharm, BALAXI PHARMACEUTICALS and Mercury Labs.

### Is Alpa Laboratories a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Alpa Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ALPA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.